| Literature DB >> 35040798 |
Yiwen Wang1, Xingkang Liu1,2, Weimin Wang3, Yanyun Shi3, Xiaojian Ji1, Lidong Hu1, Lei Wang1, Yiquan Yin4, Siyuan Xie2, Jian Zhu1, Jianglin Zhang1, Wei Jiao2, Feng Huang1,5.
Abstract
BACKGROUND: Clinical practice guidelines recommend that exercise is essential in the self-management of ankylosing spondylitis (AS). Attending supervised interventions requiring periodic medical center visits can be difficult and patients may decline participation, whereas effective home-based exercise interventions that do not require regular medical center visits are likely to be more accessible for AS patients.Entities:
Keywords: RCT; ankylosing spondylitis; combined exercise; exercise; home-based exercise; photoplethysmography; randomized controlled trial; spondyloarthritis; wearable; wearable technology
Mesh:
Year: 2022 PMID: 35040798 PMCID: PMC8808346 DOI: 10.2196/29703
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Figure 1Screenshots from the treatment app. Text has been translated from Chinese to English for illustration purposes.
Figure 2Treatment assignments and withdrawal in the intention-to-treat population. ITT: intention-to-treat.
Baseline characteristics of patients with ankylosing spondylitis enrolled in the trial.
| Characteristics | Intervention group (n=26) | Control group (n=28) | |
| Age at baseline (years), mean (SD) | 31.2 (6.3) | 33.2 (6.2) | |
| Male gender, n (%) | 20 (77) | 21 (75) | |
| Married, n (%) | 16 (62) | 18 (64) | |
| HLA-B27a positive, n (%) | 24 (92) | 25 (89) | |
| Disease duration (years), mean (SD) | 10.9 (5.5) | 10.1 (6.1) | |
| Height (cm), mean (SD) | 173.6 (7.9) | 172.0 (8.6) | |
| Weight (kg), mean (SD) | 67.7 (11.1) | 70.5 (12.1) | |
| BMI (kg/m2), mean (SD) | 22.4 (2.8) | 23.8 (3.3) | |
|
| |||
|
| AAUb | 5 (19) | 2 (7) |
|
| IBDc | 1 (4) | 0 |
|
| Psoriasis | 0 | 0 |
|
| Heel pain | 6 (23.) | 5 (18) |
|
| Hip pain | 3 (12) | 4 (14) |
|
| |||
|
| Enthesitis | 6 (23) | 10 (36) |
|
| Peripheral arthritis | 4 (15) | 3 (11) |
| PGAd, mean (SD) | 2.9 (1.5) | 3.2 (1.1) | |
| PhGAe, mean (SD) | 2.9 (1.2) | 3.2 (1.1) | |
| Total pain, mean (SD) | 2.1 (1.5) | 2.8 (1.4) | |
| Nocturnal pain, mean (SD) | 2.5 (2.1) | 2.5 (1.5) | |
| ASDASf, mean (SD) | 1.8 (0.5) | 1.7 (0.4) | |
| BASDAIg, mean (SD) | 2.0 (0.8) | 2.2 (0.6) | |
| BASMIh, mean (SD) | 1.2 (1.3) | 1.4 (1.7) | |
| BASFIi, mean (SD) | 1.1 (1.1) | 1.0 (0.8) | |
| ASAS HIj, mean (SD) | 2.7 (2.5) | 3.0 (2.9) | |
| ESRk (mm/hour) | 12.8 (10.0) | 10.7 (9.7) | |
| CRPl (mg/L) | 5.7 (6.5) | 3.0 (2.4) | |
| NSAIDsm, n (%) | 18 (69) | 22 (79) | |
| csDMARDsn, n (%) | 5 (19) | 8 (29) | |
| Corticosteroids, n (%) | 0 | 0 | |
aHLA-B27: human leukocyte antigen B27.
bAAU: acute anterior uveitis.
cIBD: inflammatory bowel disease.
dPGA: patient global assessment.
ePhGA: physician global assessment.
fASDAS: Ankylosing Spondylitis Disease Activity Score.
gBASDAI: Bath Ankylosing Spondylitis Disease Activity Index.
hBASMI: Bath Ankylosing Spondylitis Metrology Index.
iBASFI: Bath Ankylosing Spondylitis Functional Index.
jASAS HI: Assessment of Spondyloarthritis International Society Health Index.
kESR: erythrocyte sedimentation rate.
lCRP: C-reactive protein.
mNSAID: nonsteroidal anti-inflammatory drug.
ncsDMARD: conventional synthetic disease-modifying antirheumatic drug.
Figure 3Barriers to being active. Barriers to being active were analyzed among patients who followed <80% of the prescribed exercise protocol in the intervention group.